TNKS and colorectal carcinoma: Recently developed tankyrase‐specific catalytic inhibitors are serving as tool compounds and promising preclinical leads for the treatment of CRC and other Wnt‐dependent conditions (Lau et al.,2013; see Haikarainen et al.,2014a).